Share price
₹35.7 latest close · −10.7% over the last 90 sessions
₹35.7 month-end · −0.1% over 12 months
₹35.7 month-end · −14.9% since Jun '25
52-week range ₹24.55 to ₹62.40 · 1-year volatility 88.5%
Was the rally earned?
- The share price was roughly flat over 1 year (-0%).
- The share count barely moved.
What do "pts" mean?
"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.
Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.
Not shown for 3 years and 5 years: earnings were negative at one end, or there is not enough history.
Net profit is trailing twelve months as reported with a 60-day lag.
How rough has the ride been?
Drawdown from peak
Largest drawdowns
-62.3% (2023-11 peak to 2026-01 low, not yet recovered)
Where does it rank among Health Technology peers?
Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).
Where it ranks today
- ROCE78th
- Revenue growth98th
- EPS growth88th
- Debt/equity ↓10thflat vs a year ago
- Cash cycle ↓56th▲ 12 pts vs a year ago
- P/E ↓100th▲ 3 pts vs a year ago
- 12M momentum40thflat vs a year ago
Rank history
Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.
The Health Technology sector page Watch it move against Health Technology in the Observatory
What is the price implying?
At a P/E of 3.7x, the price would imply about −2.6%/yr earnings growth for 10 years under the same assumptions, but it is not ranked.
Fewer than six years of annual earnings are available, which is too little to measure delivered growth.
“Implied growth” is what the current price would require under our stated assumptions, not what we expect.
What prices imply across Health Technology The market-wide Expectations lists
Key figures
- Share Priceclose 8 Nov
- ₹35.70
- P/E
- 3.7x
- ROCE
- 23.2%
- Market Cap
- ₹15 cr
- Revenue (TTM)
- ₹71 cr
- P/S
- 0.2x
- P/B
- 0.7x
- ROE
- 20.1%
- Debt / Equity
- 0.9x
- Promoter Holding
- 53.5%
- 12M Momentum
- -0.1%
52-week range
Price risk
Balance sheet & cash
Are profits backed by cash?
Other income reliance25%Near threshold
Other income as a share of pre-tax profit (trailing twelve months): 24.8%. Bands: below 15%, 15% to 35%, above 35%.
Tax rate—Not enough data
Not enough reported data to compute this.
Cash conversion—Not enough data
Not enough reported data to compute this.
Free cash flow—Not enough data
Not enough reported data to compute this.
Receivable days vs history—Not enough data
Not enough reported data to compute this.
Capital work in progress—Not enough data
Not enough reported data to compute this.
Payable days—Not enough data
Not enough reported data to compute this.
Tap a check to see how it is measured
How to read this
Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.
Who has been buying and selling?
- Over 2 years, promoters trimmed 16.4 pts.
- The number of shareholders fell from 580 to 484 (-17%) between Mar 2024 and Jun 2026.
Holdings, Jun '26
How each group changed
Number of shareholders
Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.
What happened next to similar setups
- We found 50 past situations where a non-financial company looked like SUNREST LIFESCIENCE LIMITED today on valuation, return on capital, debt, growth, price momentum and size.
- Over the following 12 months the middle half of them returned −21% to +60% vs the market, against −1% for all non-financial companies in the same months.
- The gap against the base rate (+23.5%, 80% range −0.6% to +39.8%) is within what chance and overlapping periods produce.
Where the 50 outcomes landed
Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 8 beyond the range shown, drawn at the edge
50 past situations · 50 companies · 36 months · 2020–2025
The closest matches
| Company | When | P/E | ROCE | 12M mom. | Drawdown | Next 12 months |
|---|---|---|---|---|---|---|
| DSSL Technology Services |
Jan 2020 | 5x | 21% | −18% | −29% | +90% |
| LAXMICOT Process Industries |
Mar 2023 | 6x | — | −5% | −45% | +1% |
| CMRSL Commercial Services |
Jun 2024 | 13x | 30% | +44% | −16% | −49% |
| LAGNAM Process Industries |
Nov 2022 | 4x | 22% | +26% | −44% | +27% |
| SALONA Process Industries |
Aug 2022 | 7x | 22% | +25% | −26% | −3% |
Show the other 3 matches
| Company | When | P/E | ROCE | 12M mom. | Drawdown | Next 12 months |
|---|---|---|---|---|---|---|
| AGARIND Process Industries |
Dec 2020 | 4x | 17% | +28% | −13% | +181% |
| KHAITANLTD Consumer Durables |
Aug 2025 | 7x | — | +10% | −32% | +20% |
| NAGREEKCAP Finance |
Oct 2024 | 2x | 32% | +50% | −20% | +27% |
How reliable is this?
Matched on P/E, P/S, ROCE, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high and size. Closest on: 12-month momentum, drawdown from 12-month high and P/S. Not used (unavailable for this company): operating margin and volatility. One match per company and at most 7 from any one month.
Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.
What changed?
3 events since Dec '25
- JunResultsRevenue (TTM) reached a new high of ₹71 cr.
- JanPriceFell 62% from the Nov 2023 peak to the Jan 2026 low.
- DecPromoterPromoter holding fell 15.9 pts to 54.0%.
Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.
Where price and fundamentals disagree, market-wide Rewind the whole market to any month
Monthly history18 months · 2025-06 to 2026-11
| Month | P/E | Revenue (TTM) | ROE | ROCE | Debt / Equity |
|---|---|---|---|---|---|
| 2026-11 | 3.7x | ₹71 cr | 20.1% | 23.2% | 0.9x |
| 2026-10 | 4.1x | ₹71 cr | 20.1% | 23.2% | 0.9x |
| 2026-09 | 4.0x | ₹71 cr | 20.1% | 23.2% | 0.9x |
| 2026-08 | 4.1x | ₹71 cr | 20.1% | 23.2% | 0.9x |
| 2026-07 | 3.5x | ₹71 cr | 20.1% | 23.2% | 0.9x |
| 2026-06 | 3.3x | ₹71 cr | 20.1% | 23.2% | 0.9x |
| 2026-05 | 7.0x | ₹33 cr | 12.3% | — | 0.7x |
| 2026-04 | 7.2x | ₹33 cr | 12.3% | — | 0.7x |
| 2026-03 | 7.4x | ₹33 cr | 12.3% | — | 0.7x |
| 2026-02 | 8.0x | ₹33 cr | 12.3% | — | 0.7x |
| 2026-01 | 5.9x | ₹33 cr | 12.3% | — | 0.7x |
| 2025-12 | 7.4x | ₹33 cr | 12.3% | — | 0.7x |
| 2025-11 | 7.6x | ₹33 cr | 12.3% | — | 0.7x |
| 2025-10 | 8.7x | ₹33 cr | 12.3% | — | 0.7x |
| 2025-09 | 8.4x | ₹33 cr | 12.3% | — | 0.7x |
| 2025-08 | 8.7x | ₹33 cr | 12.3% | — | 0.7x |
| 2025-07 | 9.1x | ₹33 cr | 12.3% | — | 0.7x |
| 2025-06 | 9.0x | ₹33 cr | 12.3% | — | 0.7x |